# Jemperli (dostarlimab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/dostarlimab

> The PDUFA target action date for Jemperli (dostarlimab), sponsored by GSK plc (GSK), is Feb 2027, for previously untreated stage II and III mismatch repair deficient. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Jemperli (dostarlimab) |
| Codes | GSK4057190, TSR-042, GSK4057190A |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications | [stage ii and iii microsatellite instability-high](https://sec-api.dev/indications/stage-ii-and-iii-microsatellite-instability-high), untreated stage ii/iii dmmr/msi-h locally advanced rectal cancer, stage ii/iii mismatch repair deficient/microsatellite instability-high, previously untreated stage ii and iii mismatch repair deficient, Endometrial Carcinoma, [Neoplasms, Rectal](https://sec-api.dev/indications/neoplasms-rectal), Colonic Neoplasms, [Carcinoma](https://sec-api.dev/indications/carcinoma) |
| Modality | antibody |
| FDA designations | breakthrough, fast track, priority review |

## Timeline

### June 30, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Lung Cancer, Non-Small Cell.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06472076 (A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-30 (ACTUAL); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06472076

### July 13, 2026: interim data readout

- Status: completed, positive. Date confidence: exact. Stage: 2. Indication: stage II/III mismatch repair deficient/microsatellite instability-high.
- First seen 2026-07-13, last confirmed 2026-07-13.
- SEC Form 8-K (accession 0001654954-26-006614): "GSK plc (LSE/NYSE: GSK) today announced positive interim results from the registrational phase II AZUR-1 trial of Jemperli (dostarlimab) in patients with stage II/III mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) locally advanced rectal cancer." https://www.sec.gov/Archives/edgar/data/1131399/000165495426006614/a9768l.htm

### September 10, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Neoplasms, Head and Neck.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06062420 (A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-10 (ACTUAL); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06062420

### Sep to Dec 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Neoplasms, Head and Neck.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06062420 (A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-10 (ACTUAL); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06062420

### October 19, 2026: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: stage II and III microsatellite instability-high.
- First seen 2026-10-19, last confirmed 2026-10-19.
- SEC Form 8-K (accession 0001654954-26-009036): "GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) locally advanced rectal cancer under the accelerated approval pathway." https://www.sec.gov/Archives/edgar/data/1131399/000165495426009036/a5712z.htm

### October 26, 2026: interim data readout

- Status: completed, positive. Date confidence: exact. Stage: 2. Indication: stage II and III microsatellite instability-high.
- First seen 2026-10-26, last confirmed 2026-10-26.
- SEC Form 8-K (accession 0001654954-26-009130): "GSK plc (LSE/NYSE: GSK) today announced positive interim results from the phase II AZUR-1 trial evaluating Jemperli (dostarlimab) monotherapy as a standalone treatment approach in adults with stage II and III microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) locally advanced rectal cancer." https://www.sec.gov/Archives/edgar/data/1131399/000165495426009130/a3301a.htm

### October 26, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Lung Cancer, Non-Small Cell.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05565378 (A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-26 (ACTUAL); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT05565378

### Oct 2026 to Jan 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Lung Cancer, Non-Small Cell.
- First seen 2025-02-27, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05565378 (A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-26 (ACTUAL); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT05565378
- Press release filed with the SEC (EX-99) (accession 0001193125-26-088239): "Top-line data expected in Q4 2026 o JADE - pivotal Phase 3 - dostarlimab monotherapy versus placebo in locally advanced unresected head and neck squamous cell carcinoma (PD-L1 hiPghD-L1 CPS≥1) post chemoradiation" https://www.sec.gov/Archives/edgar/data/1370053/000119312526088239/anab-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001370053-25-000088): "▪Top-line data expected in H2 2026; U.S. FDA Breakthrough Therapy Designation" https://www.sec.gov/Archives/edgar/data/1370053/000137005325000088/q32025earningsrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-088239): "Top-line data expected in 2026; U.S. FDA Breakthrough Therapy Designation" https://www.sec.gov/Archives/edgar/data/1370053/000119312526088239/anab-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001370053-25-000045): "◦GSK anticipates top-line data in 2026 from AZUR-1 pivotal Phase 2 trial of dostarlimab monotherapy in patients with untreated stage II/III dMMR/MSI-H locally advanced rectal cancer" https://www.sec.gov/Archives/edgar/data/1370053/000137005325000045/q12025earningsrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001370053-25-000023): "•GSK anticipates top-line data in 2026 from AZUR-1 pivotal Phase 2 trial of dostarlimab monotherapy in patients with untreated stage II/III dMMR/MSI-H locally advanced rectal cancer" https://www.sec.gov/Archives/edgar/data/1370053/000137005325000023/q42024earningsrelease.htm

### Nov 2026 to Feb 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Neoplasms, Rectal.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05723562 (A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-02 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT05723562

### Nov 2026 to Feb 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Neoplasms, Colon.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06567782 (A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06567782

### November 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Neoplasms, Rectal.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05723562 (A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-02 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT05723562

### November 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Neoplasms, Colon.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06567782 (A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06567782

### Dec 2026 to Mar 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06317311 (A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06317311

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06317311 (A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06317311

### Feb 2027: PDUFA date

- Status: scheduled. Date confidence: month. Indication: previously untreated stage II and III mismatch repair deficient.
- First seen 2026-08-24, last confirmed 2026-11-12.
- SEC Form 8-K (accession 0001654954-26-007798): "FDA has assigned a PDUFA action date of February 2027." https://www.sec.gov/Archives/edgar/data/1131399/000165495426007798/a7607r.htm
- SEC Form 10-Q (accession 0001193125-26-458494): "In August 2026, the FDA accepted the sBLA for Jemperli in patients with previously untreated stage II and III mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) locally advanced rectal cancer with a target action date of February 2027." https://www.sec.gov/Archives/edgar/data/1370053/000119312526458494/anab-20260930.htm

### Oct 2027 to Jan 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Neoplasms, Rectal.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06640049 (A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10-24 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06640049

### October 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Neoplasms, Rectal.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06640049 (A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10-24 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06640049

### Jun to Sep 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Neoplasms, Head and Neck.
- First seen 2026-03-03, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06256588 (A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06256588
- Press release filed with the SEC (EX-99) (accession 0001193125-26-088239): "Top-line data expected in 2028" https://www.sec.gov/Archives/edgar/data/1370053/000119312526088239/anab-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-088239): "Top-line data expected in 2028 o AZUR-4 - Phase 2 - dostarlimab plus chemotherapy versus standard of care (chemotherapy) in untreated stage III MMRp/MSS resectable colon cancer" https://www.sec.gov/Archives/edgar/data/1370053/000119312526088239/anab-ex99_1.htm

### June 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Neoplasms, Head and Neck.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06256588 (A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06256588

### Mar to Jun 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Colonic Neoplasms; Neoplasms, Colon.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05855200 (Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-19 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT05855200

### March 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Colonic Neoplasms; Neoplasms, Colon.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05855200 (Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-19 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT05855200

### Mar to Jun 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Neoplasms, Endometrial.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07108270 (A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-03-31 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07108270

### Mar to Jun 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Neoplasms, Rectal.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07740720 (A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-03-13 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07740720

### March 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Neoplasms, Rectal.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07740720 (A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-03-13 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07740720

### March 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Neoplasms, Endometrial.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07108270 (A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-03-31 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07108270

### Nov 2030 to Feb 2031: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Endometrial Carcinoma; Neoplasms, Endometrial.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07860450 (Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-11-05 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07860450

### November 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Endometrial Carcinoma; Neoplasms, Endometrial.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07860450 (Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-11-05 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07860450

## Same indication

- [Tagrisso® (osimertinib)](https://sec-api.dev/pdufa/osimertinib) (AZN)
- [PF-08634404](https://sec-api.dev/pdufa/pf-08634404) (PFE)

Calendar months: [November 2026](https://sec-api.dev/fda-calendar/2026-11), [December 2026](https://sec-api.dev/fda-calendar/2026-12), [October 2027](https://sec-api.dev/fda-calendar/2027-10), [June 2028](https://sec-api.dev/fda-calendar/2028-06)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/dostarlimab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Jemperli (dostarlimab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/dostarlimab

```bibtex
@misc{secapidev_pdufa_dostarlimab_20261116,
  title        = {Jemperli (dostarlimab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/dostarlimab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_dostarlimab_20261116","title":"Jemperli (dostarlimab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/dostarlimab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
